Stockreport

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

Alkermes plc - Ordinary Shares  (ALKS) 
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
PDF – Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to [Read more]